share_log

Raymond James Thinks Haemonetics Growth Is 'Underappreciated'

Raymond James Thinks Haemonetics Growth Is 'Underappreciated'

雷蒙德·詹姆斯认为血液学的增长被低估了
Benzinga Real-time News ·  2022/07/01 12:20
  • Earlier this week, Raymond James attended Haemonetics Corp's (NYSE:HAE) Investor Day, where the management team presented a new Long-Range Plan (LRP), including some upside on the profitability, outlining each business unit's positioning and pipeline. 
  • According to the analysts, the plan implies an upside to expectations, despite some conservatism and back-end weight.
  • Raymond James rolled the FY25 EPS estimate of $3.80 vs. the sub-$3.50 consensus into the event. 
  • See the investor presentation here.
  • Though plasma was a major part of the discussion, the team highlighted the other portions of the business that can be viewed as moving towards a more diversified player.
  • The analysts note that vascular closure and hemostasis management are poised for more growth and offer a core set of offerings to build both organically and inorganically.
  • At ~14x CY22 EBITDA and ~22x CY22 EPS, Raymond James thinks the stock remains attractive in the context of stable growth, with Outperform rating unchanged and the price target raised from $63 to $76 (15% upside).
  • The analysts believe Haemonetics is positioned for healthy double-digit earnings growth underappreciated at current valuations.
  • Price Action: HAE shares are up 1.18% at $65.95 during the market session on the last check Friday.
  • 本周早些时候，雷蒙德·詹姆斯出席者血液科技公司的(纽约证券交易所股票代码：HAE)投资者日，管理团队提出了新的长期计划(LRP)，包括盈利能力的一些上行，概述了每个业务部门的定位和正在进行的工作。
  • 根据分析师的说法，该计划意味着预期的上升，尽管存在一些保守主义和后端权重。
  • 雷蒙德·詹姆斯将25财年每股收益预期定为3.80美元，而不是普遍预期的3.50美元。
  • 点击此处查看投资者演示文稿。
  • 尽管血浆是讨论的主要部分，但该团队强调了该业务的其他部分，可以被视为正在朝着更多元化的方向发展。
  • 分析师指出，血管闭合和止血管理有望实现更多增长，并提供一套核心产品，以有机和非有机方式构建。
  • 在~14倍的CY22 EBITDA和~22倍的CY22 EPS，Raymond James认为该股在稳定增长的背景下仍然具有吸引力，表现优于预期的评级不变，目标价从63美元上调至76美元(上涨15%)。
  • 分析人士认为，血液学 为健康的两位数收益增长做好了准备，在当前估值下被低估了。
  • 价格行动：海航股价在周五尾盘上涨1.18%，至65.95美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发